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Abstract
Eicosanoids	are	20-carbon	fatty	acids,	where	the	usual	focus	is	the	polyunsaturated	analogue
arachidonic	acid	and	its	metabolites.	Arachidonic	acid	is	thought	primarily	to	derive	from
phospholipase	A2	action	on	membrane	phosphatidylcholine,	and	may	be	re-cycled	to	form
phospholipid	through	conjugation	with	coenzyme	A	and	subsequently	glycerol	derivatives.	Oxidative
metabolism	of	arachidonic	acid	is	conducted	through	three	major	enzymatic	routes:	cyclooxygenases;
lipoxygenases	and	cytochrome	P450-like	epoxygenases,	particularly	CYP2J2.	Isoprostanes	are
structural	analogues	of	the	prostanoids	(hence	the	nomenclature	D-,	E-,	F-isoprostanes	and
isothromboxanes),	which	are	produced	in	the	presence	of	elevated	free	radicals	in	a	non-enzymatic
manner,	leading	to	suggestions	for	their	use	as	biomarkers	of	oxidative	stress.	Molecular	targets	for
their	action	have	yet	to	be	defined.
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